Navigation Links
Indivumed Appoints Annette Kassen as Vice President Clinical Research
Date:4/9/2008

HAMBURG, Germany, April 9 /PRNewswire/ -- Indivumed GmbH, the leading provider of products and services enabling the individualized diagnosis and therapy of cancer, announces the appointment of Annette Kassen, Ph.D., to the newly created position of Vice President Clinical Research.

Annette Kassen has spent the last 14 years of her career in basic and clinical research in the field of oncology. At Indivumed she will be responsible for the further development and expansion of the company's clinical research activities and services. Dr Kassen joins from medac GmbH, a Hamburg based pharmaceutical company, where she worked as a project leader conducting phase II/III clinical trials in Europe.

After receiving her Ph.D. from Ruhr-Universitat Bochum in 1994, Annette Kassen was a post-doctoral fellow at Northwestern-University Medical School, Chicago, focussing on the androgen regulation of human prostate cancer cells. She continued her career as Head of Research Laboratories at the University Hospital Department of Urology, Ruhr-Universitat Bochum. She joined medac in 1999 and received her "Masters of Public Health" from Hamburg University of Applied Sciences in 2004.

"Annette Kassen brings with her very valuable knowledge concerning the continuously growing regulatory requirements in clinical research," says Prof. Hartmut Juhl, Chief Executive Officer and Founder of Indivumed. "Moreover, she is a skilful complement to our team and I am confident that Indivumed will benefit from her experience in order to implement and further develop highest clinical research quality standards at Indivumed."

Dr. Kassen said: "There is a great need for effective, sophisticated, and individualized therapies in the treatment of oncologic diseases. Indivumed has the potential to face this challenge successfully and I am very happy to contribute to both the development of new therapeutic strategies as well as the company's success."

About Indivumed

Indivumed is a privately held biotech company focused on the generation, characterization and analysis of highly standardized biological samples from human cancer. Founded in 2002 and headquartered in Hamburg, Germany, with a subsidiary in Kensington, Maryland, USA, Indivumed has cooperation agreements with all major oncological hospitals in the Hamburg metropolitan area as well as with Georgetown University Hospital, Washington, D.C. Indivumed's current tumor biobank of over 8,000 patient-cases, collected with a mean cold ischemia time of less than eight minutes, serves as a resource for Indivumed's internal cancer research in biomarkers and primary cell drug screening as well as for the use of pharmaceutical and biopharma partners through tumor biobank access and a variety of services, such as e.g. IHC and drug profiling.


'/>"/>
SOURCE Indivumed
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
2. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
3. Codexis Appoints Singapore Laboratories Managing Director
4. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
5. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
6. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
7. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
8. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
9. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
10. NeurogesX Appoints New Director to the Board
11. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... BALTIMORE, Md. (PRWEB) , ... October 11, 2017 ... ... for digital pathology, announced today it will be hosting a Webinar titled, “Pathology ... of  Advanced Pathology Associates , on digital pathology adoption best practices and how ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology ... drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription ... is able to cross the cell membrane and bind intracellular STAT3 and inhibit ...
(Date:10/10/2017)... Oct. 10, 2017 International research firm Parks Associates ... speak at the TMA 2017 Annual Meeting , October 11 in ... the residential home security market and how smart safety and security products ... Parks Associates: Smart ... "The residential security market ...
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer ... first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , With ... with the challenge of how to continue to feed a growing nation. At the ...
Breaking Biology Technology:
(Date:5/16/2017)... DALLAS , May 16, 2017   ... for health organizations, and MD EMR Systems ... certified development partner for GE, have established a ... Patient Portal product and the GE Centricity™ products, ... Centricity EMR. These new integrations ...
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. (NASDAQ: ... announces the filing of its 2016 Annual Report on Form 10-K ... Commission. ... 10-K is available in the Investor Relations section of the Company,s ... the SEC,s website at http://www.sec.gov . 2016 Year ...
(Date:4/11/2017)... No two people are believed to ... York University Tandon School of Engineering and Michigan ... partial similarities between prints are common enough that ... and other electronic devices can be more vulnerable ... in the fact that fingerprint-based authentication systems feature ...
Breaking Biology News(10 mins):